Cue Biopharma Inc Valor contable por acción
¿Qué es el Valor contable por acción de Cue Biopharma Inc?
El Valor contable por acción de Cue Biopharma Inc es 0.17
¿Cuál es la definición de Valor contable por acción?
El valor en libros por acción es el activo de una empresa menos el pasivo dividido por el número de acciones en circulación.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valor contable por acción de compañías en Sector Health Care en NASDAQ en comparadas con Cue Biopharma Inc
¿Qué hace Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Empresas con valor contable por acción similar a Cue Biopharma Inc
- Tortoise Acquisition tiene Valor contable por acción de 0.17
- Orex Minerals tiene Valor contable por acción de 0.17
- Netfin Acquisition tiene Valor contable por acción de 0.17
- Aclaris Therapeutics Inc tiene Valor contable por acción de 0.17
- ZW Data Action Technologies Inc tiene Valor contable por acción de 0.17
- RTW Retailwinds tiene Valor contable por acción de 0.17
- Cue Biopharma Inc tiene Valor contable por acción de 0.17
- CURE Pharmaceutical tiene Valor contable por acción de 0.17
- Cobra Venture tiene Valor contable por acción de 0.17
- Roblox tiene Valor contable por acción de 0.17
- DLC Asia tiene Valor contable por acción de 0.17
- Blue Star Foods tiene Valor contable por acción de 0.17
- Kingsgate Consolidated tiene Valor contable por acción de 0.17